VERGANI, BARBARA
VERGANI, BARBARA
Universita' degli Studi di MILANO
Monkeypox: A Histopathological and Transmission Electron Microscopy Study
2023 C. Moltrasio, F.L. Boggio, M. Romagnuolo, R. Cagliani, M. Sironi, A. Di Benedetto, A.V. Marzano, B.E. Leone, B. Vergani
Automatic quantification of histochemical images of cancerous tissue samples: a method based on a computational model of human color vision
2019 E. Casiraghi, B. Vergani, B. Barricelli, S. Liberini, B.E. Leone, A. Rizzi
Evidence for a role of autoinflammation in early-phase psoriasis
2019 D. Fanoni, L. Venegoni, B. Vergani, S. Tavecchio, A. Cattaneo, B.E. Leone, E. Berti, A.V. Marzano
Ki67 nuclei detection and ki67-index estimation : a novel automatic approach based on human vision modeling
2019 B.R. Barricelli, E. Casiraghi, J. Gliozzo, V. Huber, B.E. Leone, A. Rizzi, B. Vergani
pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma
2018 O. Kuchuk, A. Tuccitto, D. Citterio, V. Huber, C. Camisaschi, M. Milione, B. Vergani, A. Villa, M. Alison, S. Carradori, C. Supuran, L. Rivoltini, C. Castelli, V. Mazzaferro
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment
2017 M. Tazzari, V. Indio, B. Vergani, L. De Cecco, F. Rini, T. Negri, C. Camisaschi, M. Fiore, S. Stacchiotti, G.P. Dagrada, P.G. Casali, A. Gronchi, A. Astolfi, M.A. Pantaleo, A. Villa, C. Lombardo, F. Arienti, S. Pilotti, L. Rivoltini, C. Castelli
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy
2015 D. Miglietta, C. De Palma, C. Sciorati, B. Vergani, V. Pisa, A. Villa, E. Ongini, E. Clementi
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
2014 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, B. Vergani, M. Morosi, E. Colella, M. Galli, S. Rusconi
Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30+ T lymphocytes with progression
2014 V. Vallacchi, E. Vergani, C. Camisaschi, P. Deho, A.D. Cabras, M. Sensi, L. De Cecco, N. Bassani, F. Ambrogi, A. Carbone, F. Crippa, B. Vergani, P. Frati, F. Arienti, R. Patuzzo, A. Villa, E. Biganzoli, S. Canevari, M. Santinami, C. Castelli, L. Rivoltini, M. Rodolfo
Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-Institution retrospective study before and after the introduction of HAART
2013 M. Franzetti, F. Adorni, C. Parravicini, B. Vergani, S. Antinori, L. Milazzo, M. Galli, A.L. Ridolfo
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi
Tipranavir in the Protease Inhibitors Arena
2011 B. Vergani, S. Rusconi
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi